 |
[Apha Biz=(Chicago) Reporter Paul Lee] Hana Securities lowered the target price of Celltrion Healthcare from 110,000 won to 95,000 won on the 16th. The closing price on the 14th is 70,500 won.
"Celltrion Healthcare recorded operating profit of 34.1 billion won in the second quarter on a consolidated basis, below consensus operating profit of 54.6 billion won," said researcher Park Jae-kyung. "As a result, this year's operating profit will be lowered from the previous estimate of 253.2 billion won to 197.1 billion won."
"Celltrion Healthcare's Yuflyma has been sluggish in U.S. private insurance coverage. Medicare·Medicaid, which has not yet listed Humira Similar (Prime registered as Cyltezo on Medicare formulary), has succeeded in negotiating with major insurance companies," Hana Securities said. "This year due to the establishment of the U.S. direct sales system, it is difficult to confirm sales growth and profitability improvement."
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
